Cargando…

Alemtuzumab/cladribine/natalizumab: Lymphopenia and COVID-19 infection: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642202/ http://dx.doi.org/10.1007/s40278-021-06348-7

Ejemplares similares

Cladribine: Lymphopenia: case report
Publicado: (2021)

Cladribine: Lymphopenia: 2 case reports
Publicado: (2020)

Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports
Publicado: (2021)

Cladribine/hydroxychloroquine: COVID-19-pneumonia, lymphopenia and off label use: case report
Publicado: (2020)

Alemtuzumab: COVID-19 infection: case report
Publicado: (2020)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Natalizumab: COVID-19 infection: case report
Publicado: (2021)

Natalizumab: COVID-19 infection: 19 case reports
Publicado: (2022)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Alemtuzumab: COVID-19 infection and severe depletion of T-lymphocyte: case report
Publicado: (2020)

Alemtuzumab: Infections: 4 case reports
Publicado: (2020)

Therapy with cladribine is efficient and safe in patients previously treated with natalizumab
por: Möhn, Nora, et al.
Publicado: (2019)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Fingolimod: Lymphopenia and COVID-19 infection complicated by pneumonia: case report
Publicado: (2020)

COVID-19-vaccine/mycophenolate: Cytomegalovirus infection and lymphopenia: case report
Publicado: (2022)

Natalizumab: Pneumonia caused by COVID-19: case report
Publicado: (2020)

Both cladribine and alemtuzumab may effect MS via B-cell depletion
por: Baker, David, et al.
Publicado: (2017)

Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
por: Wang, Li, et al.
Publicado: (2018)

Alemtuzumab: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Mycophenolate mofetil/prednisone/tacrolimus: COVID-19 and lymphopenia: case report
Publicado: (2021)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Natalizumab: Coronavirus disease-2019 infection: 6 case reports
Publicado: (2022)

Immunosuppressants: Lymphopenia and thrombocytopenia: 5 case reports
Publicado: (2021)

Natalizumab: Progressive multifocal leukoencephalopathy: case report
Publicado: (2021)

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2023)

Alemtuzumab-associated diffuse alveolar damage – a case report
por: Bayas, Antonios, et al.
Publicado: (2020)

Alemtuzumab/methylprednisolone: Coronavirus disease-2019: 2 case reports
Publicado: (2020)

Hydroxycarbamide: Worsening thrombocytopenia and unmasking of lymphopenia: case report
Publicado: (2021)

Methotrexate/steroids: Lymphopenia and Pneumocystis pneumonia: case report
Publicado: (2021)

Natalizumab: Pneumonitis and peripheral blood eosinophilia: case report
Publicado: (2022)

Immunosuppressants: Lymphopenia, neutropenia and prolongation of the coronavirus disease 2019 (COVID-19) viral clearance: case report
Publicado: (2021)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Multiple drugs: SARS-CoV-2 infection and lymphopenia: 3 case reports
Publicado: (2021)

Alemtuzumab as initial therapy for Sézary syndrome: A report of 2 cases
por: Brumfiel, Caitlin M., et al.
Publicado: (2020)

Antithymocyte-globulin/mycophenolate-mophetil: Lymphopenia: 3 case reports
Publicado: (2021)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies
por: Holmøy, Trygve, et al.
Publicado: (2017)

Immunosuppressants: Severe acute respiratory syndrome coronavirus-2 infection and lymphopenia: 2 case reports
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dt3je8rq62ik952i4dt3tj57o6